- Abstract
- Core Tip
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (142)
- Timeline of Article Publication (5)
- Authors Evaluation (3)
- Article Quality Tracking (0)
- Reference Citation Analysis (3)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4599)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 7, 2024 (publication date) through Jul 21, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lin ZP, Hu XL, Chen D, Huang DB, Zou XG, Zhong H, Xu SX, Chen Y, Li XQ, Zhang J. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma. World J Gastroenterol 2024; 30(17): 2321-2331 [PMID: 38813052 DOI: 10.3748/wjg.v30.i17.2321] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i17/2321.htm |
| Number | Citing Articles |
| 1 |
Ying Wu, Zhenpeng Zeng, Shuanggang Chen, Danyang Zhou, Gangling Tong, Duanming Du. Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1531249
|
| 2 |
Peng Jiang, Chao Chen, Jing Tian, Fan Yang, Zhen-yu Jiang, An-xiang Hu, Bin Liu. Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Academic Radiology 2025; 32(8): 4595 doi: 10.1016/j.acra.2024.09.061
|
| 3 |
Jinpeng Li, Congcong Shi, Jiao Chen, Yue Zhao, Jiasheng Du, Jinlong Song. Risk Factors and Predictive Analysis of Acute Severe Abdominal Pain After Hepatic Artery Infusion Chemotherapy in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2025; : 289 doi: 10.2147/JHC.S494668
|
| 4 |
Yan-Cen Lu, Yu-Chen Yang, Di Ma, Jun-qing Wang, Feng-Jie Hao, Xu-xiao Chen, Yong-jun Chen. FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1471017
|